108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
病例报告：罕见的度普利尤单抗相关肺及肺外结核
Received 16 May 2025
Accepted for publication 19 August 2025
Published 2 October 2025 Volume 2025:18 Pages 5219—5222
DOI https://doi.org/10.2147/IDR.S540790
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Prof. Dr. Héctor M. Mora-Montes
Weiyan Xu,1 Jianfeng Zhong2
1Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, People’s Republic of China; 2Department of Infectious Disease, Huzhou Key Laboratory of Precision Medicine Research and Translation for Infectious Diseases, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Fifth School of Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, People’s Republic of China
Correspondence: Jianfeng Zhong, Email zhongjianfeng1206@126.com
Abstract: Dupilumab, a fully human monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα), has revolutionized the management of moderate-to-severe atopic dermatitis (AD) by inhibiting signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13). Our case report is about a 71-year-old man with a history of AD who developed pulmonary tuberculosis (PTB) and extrapulmonary tuberculosis (EPTB) after treatment with dupilumab. The mechanism is unclear, but it may be related to the fact that dupilumab inhibits the expression of pro-inflammatory response-related genes and the innate immunity of macrophages, thereby aggravating TB infection. This is the first report of PTB and EPTB associated with dupilumab treatment, and it may be useful for clinicians to enhance TB vigilance in patients receiving dupilumab therapy, particularly in endemic regions.
Keywords: dupilumab, tuberculosis, atopic dermatitis
1Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, People’s Republic of China; 2Department of Infectious Disease, Huzhou Key Laboratory of Precision Medicine Research and Translation for Infectious Diseases, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Fifth School of Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, People’s Republic of China
Correspondence: Jianfeng Zhong, Email zhongjianfeng1206@126.com
Abstract: Dupilumab, a fully human monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα), has revolutionized the management of moderate-to-severe atopic dermatitis (AD) by inhibiting signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13). Our case report is about a 71-year-old man with a history of AD who developed pulmonary tuberculosis (PTB) and extrapulmonary tuberculosis (EPTB) after treatment with dupilumab. The mechanism is unclear, but it may be related to the fact that dupilumab inhibits the expression of pro-inflammatory response-related genes and the innate immunity of macrophages, thereby aggravating TB infection. This is the first report of PTB and EPTB associated with dupilumab treatment, and it may be useful for clinicians to enhance TB vigilance in patients receiving dupilumab therapy, particularly in endemic regions.
Keywords: dupilumab, tuberculosis, atopic dermatitis